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Background. Most physicians use digital rectal examination (DRE) to help detect prostate cancer and to estimate the prostates’ size.
The accuracy of DRE is known to be limited. We evaluate the ability of doctors to palpate the whole prostate with DRE. Methods.
At time of transrectal ultrasound (TRUS) the distances from the anus to the apex and base of prostates were measured. The
TRUS’s distances were compared to the mean index ﬁnger length of our clinic doctors. Results. The ability of the urologist to reach
and examine the apex, half, three quarters and the whole prostate was in 93.7%, 66.3%, 23.2% and 3.2% of cases respectively.
Conclusions. In most cases it was impossible to palpate the whole prostate. Anatomical location and volume of the examined
prostate, as well as the length of his own index ﬁnger limit DRE and allow the examination of only a small portion of the prostate.
1.Introduction
Digital rectal examination (DRE) is widely used in medicine.
A large number of physicians perform it to estimate the
prostates’ size and/or for early detection of prostate cancer.
It is well accepted that DRE is a subjective measure and
has a high interobserver variability when estimating prostate
size. It has been reported that DRE poorly predicted actual
prostatesizecomparedtotransrectalultrasound(TRUS)[1].
Otherscomparedradicalretropubicprostatectomyspecimen
weights with prostate weight estimates using TRUS and DRE
and found that DRE correlated poorly with prostate weight
and that TRUS was superior to DRE [2].
In the prostate speciﬁc antigen (PSA) era the role of DRE
in early detection of prostate cancer is not clear. This role
w a se v a l u a t e di nan u m b e ro fl a r g et r i a l s[ 3, 4]. The cancer
detection rate for DRE was 3.2% and positive predictive
value was 21%, PSA or a combination of DRE and PSA
were superior to DRE alone for the diagnosis prostate cancer
[3]. The positive predictive value and sensitivity of DRE
were strongly dependent on PSA level and DRE predicted
cancer poorly in patients with low PSA values [4]. Some
havesuggestedthatDREmaybeunnecessaryinpatientswith
PSA values of 3.0 or less [5, 6], since in these patients one
wouldneedtoperform289DREstoﬁndonecaseofclinically
signiﬁcant prostate cancer.
We believe that in addition to DRE’s subjectivity, there
are other inherent limitations to DRE. When performing
DRE, prior to reaching any conclusions, the examiner should
be able to feel the whole posterior surface of the prostate.
However, in clinical practice this may not always be possible.
Patient morphometric variables as well as the length of
the examiners index ﬁnger may impact on the accuracy
of DRE. There is no data concerning these factors. One
study examined the adequacy of prostate palpation when
performing DRE during colonoscopies and concluded that
patient positioning and obesity were aﬀecting factors [7].
These observations prompted us to carry out our study.
In this study we tried to explore the limitations of DRE
fromananatomicalpointofview.Forthis,thedistancesfrom
anus to the prostate were measured in patients undergoing
TRUS. These were compared to the length of index ﬁnger
of urologists in our clinic. In other words, we examine the
ability of urologist to palpate the whole of the prostates
posterior surfaces at the time of DRE.2 ISRN Urology
2.MaterialsandMethods
In a prospective fashion, we examined patients who were
referred for prostatic biopsy at our outpatient clinic.
At time of TRUS the distances from the anus to the apex
andbaseofprostatesweremeasuredusingan8-MHzbiplane
probe (B-K medical, 8808 probe). For this purpose the probe
was marked with 0.5cm gradients from the US transverse
view crystal out to handle. All TRUS were performed with
the patients in the left decubitus position with the knees
pulled up to the chest. When the apex of the prostate was
viewed in the transverse plain, its depth from the anal verge
was noted (anal-apex distance). Then the probe was moved
in the cephalic direction until the base of the prostate was
visualized and a second measurement was noted (anal-base
distance). Index ﬁngers (from the top of the ﬁnger to the
beginningthirdinterphalangealjoint)ofourclinicurologists
were measured with a centimeter ruler.
All biopsies were done under local anesthesia using
periprostatic block with 20cc of lidocaine 1%. Systematic
transrectal biopsies were obtained using a spring-loaded
biopsy gun and 18G biopsy needle. Patients with BMI 30 or
more were excluded from the study.
To analyze the data we divided the prostatic surface
length into 4 zones. First is the distal or apical zone that
included the distal 25% of the prostate. The second is half
prostate, the third zone included 75% of surface, and fourth
zone was the whole prostate. The ability of the urologist
to palpate all prostatic zones, with DRE was examined
comparing the distances measured at the time of TRUS to
the mean urologists’ index ﬁnger length.
Commercial software (GraphPad Prism) was used for
statistical analysis. The results were expressed as mean ±
SEM or as median with range. All relationships were assessed
by Pearson correlation analysis. Contingency table with
Fisher’s exact test was used to assess the accuracy of DRE.
A level of signiﬁcance (P value) < 0.05 was considered
statistically signiﬁcant.
3. Results andDiscussion
Between March and June 2010, ninety-ﬁve men were
included in the study. The median age was 64 (range 49–82).
Median PSA was 6.94ng/mL (range 1.56–347). In Thirty-six
(38%) men this was not the ﬁrst biopsy session. The median
number of biopsies was 12 (range 8–16). In 15 men (16%)
the DRE was suspicious for prostate cancer. Median TRUS
prostatevolumewas53mL(range13.7–301)andthemedian
DRE estimated prostate volume was 40mL (range 10–80).
The correlation between TRUS measured volumes and DRE
estimated volumes was not high (Pearson r = 0.42) but
statistically signiﬁcant (P<0.0006) (Figure 1).
The median anal-apex distance was 5cm (range 3–7.5),
and anal-base distance was 10.3cm (range 7.3–15.7). The
median length of our urologists index ﬁngers was 8.25cm
(range 7–9, N = 7). Thus in most cases it was impossible
to palpate the whole posterior surface of the prostates. In
fact, the ability of the urologist to reach and examine the
apex, half prostate, three quarters, and the whole prostate
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Figure 1: The correlation between TRUS measured volumes and
DRE estimated volumes.
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Figure 2:Thecorrelationbetweenanal-basedistanceandtheTRUS
volume of prostate.
was in 93.7%, 66.3%, 23.2%, and 3.2% cases, respectively.
There was a good correlation between anal-base distance and
the TRUS volume of prostate (Pearson r = 0.72, P<0.001)
(Figure 2).
Twenty-nine (30.5%) cases of prostate cancer were
diagnosed. The sensitivity and speciﬁcity of DRE for the
diagnosis of prostate cancer were 21% and 86%, respectively.
The positive predictive value of DRE was 40%. According
to the Fisher’s exact test the DRE was an inaccurate exam
(P = 0.38).
This study demonstrated that in most cases it was
impossible to palpate the whole posterior surface of the
prostate by DRE. This is ﬁrst time that distance from anal
verge to prostate was recorded. Our ﬁndings may explain
why DRE is a poor predictor of prostate volume and has low
sensitivity for the detection prostate cancer.
3.1. DRE and Prostate Volume. The ability to estimate pros-
tate volume is very important before surgical intervention,
brachytherapy, benign prostatic hyperplasia management,ISRN Urology 3
and calculating PSA density [8–10]. According to the
available literature, DRE is an inaccurate test. DRE under-
estimates prostate size, particularly if prostate volume is
greater than 30mL [1]. In our study a strong correlation
between the anal-base distance and prostate volume was
demonstrated. It follows, then, that in larger prostates even
more of the prostatic surface would be beyond the reach of
the palpating ﬁnger making it even harder to estimate its
volume. Therefore DRE volume estimations may correlate
well with TRUS measured volumes in small glands. In our
study we found that DRE estimated volume did not correlate
well with TRUS measured volume (Pearson r = 0.42). Even
worse correlation was reported by Loeb et al. in their large
study [2]. Although, in their study they compared DRE
estimated prostatic volume with the actual weight of radical
prostatectomyspecimens.Basedonour,andothers’ﬁndings,
DRE is not a good predictor of actual prostatic volume
though it may help distinguish small prostates from large
onesandmayestimatepreciselyprostaticvolumesinpatients
with small glands.
3.2.DREandProstateCancerScreening. Thedebateconcern-
ing prostate cancer screening is still underway. Even after the
publication of the results of large trials from USA [11]a n d
Europe [12]thequestion“toscreenornottoscreen”remains
unanswered.
In the US, the Prostate, Lung, Colorectal, and Ovarian
(PLCO) Cancer Screening Trial, Andriole et al. [11]r e p o r t e d
no mortality beneﬁt from combined screening with PSA
testing and DRE over a median followup of 11 years. In
the European Randomized Study of Screening for Prostate
Cancer (ERSPC) trial, Schr¨ oder et al. [12] reported that PSA
screening without DRE was associated with a 20% relative
reduction in the death rate from prostate cancer at a median
followup of 9 years, with an absolute reduction of about 7
prostatecancerdeathsper10,000menscreened.InthePLCO
studyDREwasusedasascreeningtoolwhereasintheERSPC
trial DRE was used only in a small portion of the patients.
One may conclude then that DRE is not helpful in detection
prostate cancer. On the other hand, DRE is an integral part
of nomograms and predictive tools for the management of
patients with prostate cancer [13–15]. And positive DRE
may predict worse prognosis comparing to normal DRE.
Gosselaar et al. [16], from the Rotterdam section of ERSPC,
point out that potentially aggressive cancers (Gleason score
7) are more prevalent among men who have an abnormal
DRE compared to normal DRE. However, Gosselaar et al,
in another study [17], state that an initially suspicious
DRE, after initial cancer-negative biopsy, did not inﬂuence
the chance for detection of cancer or signiﬁcant cancer at
later repeated biopsies. Moreover, this group of investigators
previously reported that an abnormal DRE was not an
indication for prostate biopsy in men with PSA < 3ng/mL
[4]. Interestingly Vis et al. [6] reported in their study that up
to 63% of prostate cancers were detected coincidentally and
not as a result of true positive DRE. In our study DRE was
an inaccurate predictor of prostate cancer (P = 0.38) with
low sensitivity though its speciﬁcity was 86%. According to
our morphometric ﬁndings, an examiner needs to take into
consideration, when performing DRE, that in most cases at
least part of the surface of the prostate remains out of his
reach and unexamined.
Before discarding DRE one should consider that DRE
is also an important part of the physical examination of
patients with lower urinary tract symptoms. Perineal sensa-
tion, anal tone, and the bulbocavernous reﬂex are simple and
straight forward methods to assess the neurological integrity
of the lower urinary tract [18].
There are some limitations to our study. Firstly, we did
not takeinto accounttheelasticproperty of human tissue.At
the time of DRE one may reach deeper by applying pressure
on the perineum. Also, the shape of prostate was not taken
into consideration. In large prostates, that protrude more
into the rectum the actual length of the prostate grows as the
curve is longer than a straight line. In our study we used a
straight TRUS probe to measure prostatic length therefore
the actual anal-base distance may be underestimated in some
cases. This, though, does not weaken our conclusions.
4. Conclusions
DRE is still an important and inexpensive tool for the
physician.Onemaygaininformationabouttheprostatessize
and consistency as well as the neurological function of the
lower urinary tract. However, the examiner has to consider
factors that limit the accuracy of DRE such as the anatomical
location and volume of the examined prostate, as well as
the length of his own index ﬁnger. One must remember
that in many patients these factors limit DRE and allow the
examination of only a small portion of the prostate.
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